Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)

NCT03934905 is registered in ClinicalTrials.gov with Texas Tech University Health Sciences Center as lead sponsor.

NCT NCT03934905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)
Lead sponsor
Texas Tech University Health Sciences Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2022
Completion date
June 1, 2029
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthracycline related cardiotoxicity in breast cancer